Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$1.8MCash on Hand
4mo Cash Runway
Follow COSM by emailGet an email when COSM pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about COSM, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
Mar 2027 · N/A · Upcoming Trial · A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measur Registry primary completion date, not a results date
Jul 2027 · N/A · Upcoming Trial · A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Registry primary completion date, not a results date
💰 Cash Runway & Dilution Risk
COSM holds $1.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.4M/quarter from operations,
an estimated runway of 4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:100 · High
Cash runway 4 months +40
ATM program on file since Nov 2025 +15
Shelf registration (S-3, Nov 2025) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the date of this filing.10-Q, Aug 2026
Share count +233% in a year +20
Recent financing filings on SEC EDGAR:
Nov 7, 2025 · Shelf registration with ATM program, up to $100M · S-3
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COSM and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.